

I hereby certify that this correspondence is being filed via  
EFS-Web with the United States Patent and Trademark Office  
on 1-10-07

TOWNSEND and TOWNSEND and CREW LLP

By: Endy Shaffer

**AMENDMENT UNDER 37 CFR 1.116  
EXPEDITED PROCEDURE –  
EXAMINING GROUP 1652**

**PATENT**

Attorney Docket No.: 021044-000600US  
Client Ref. No.: P.0063.01.US.UT.X00.RR

**IN THE UNITED STATES PATENT AND TRADEMARK OFFICE**

In re application of:

Esteban Masuda et al.

Application No.: 09/998,667

Filed: December 3, 2001

For: TRAC1: MODULATORS OF  
LYMPHOCYTE ACTIVATION

Customer No.: 20350

Confirmation No. 7585

Examiner: Hutson, Richard G.

Technology Center/Art Unit: 1652

**AMENDMENT UNDER 37 CFR 1.116  
EXPEDITED PROCEDURE EXAMINING  
GROUP 1652**

Commissioner for Patents  
P.O. Box 1450  
Alexandria, VA 22313-1450

Sir:

In response to the Notice of Non-Compliant Amendment mailed January 4, 2007, please enter the following amendments and remarks which mirror the Amendment Under 37 CFR 1.116 filed via EFS-Web with the U.S. Patent and Trademark Office on September 22, 2006 in response to the Office Action dated June 23, 2006 (with the exception of the listing of claims which now reflects claim 47 as being previously presented):

**Amendments to the Claims** are reflected in the listing of claims which begins on page 2 of this paper.

**Remarks/Arguments** begin on page 8 of this paper.